Lumora patent granted covering the use of its core BART technology


Lumora Ltd has been awarded European patent No. 04701994.8 covering Lumora’s proprietary ‘BART’ technology (Bioluminescent Assay in Real-Time).

The BART technology is a novel reporter system that permits the quantitative detection of nucleic acids, proteins and small molecules in real-time.  The technology has been designed to be used with isothermal nucleic acid amplification technologies, which enables quantitative molecular diagnostics to be performed rapidly with remarkably simple, robust, low-cost hardware.

Lumora is poised to introduce the benefits of molecular diagnostics to niches where the cost and complexity of present products prevents their practical application. Molecular Diagnostics is where organisms/diseases are detected and identified from miniscule amounts of DNA. It is an extremely powerful approach and one that is revolutionising the diagnosis of disease in clinical settings. However, molecular diagnostics requires costly reagents, expensive hardware and highly trained staff to operate: it’s simply too costly for many potential users to afford. Lumora’s technology greatly simplifies molecular diagnostics by coupling the detection of specific DNA molecules to a simple light output.

Dr Laurence Tisi, Acting CEO & Co-Founder of Lumora, said “The granting of the patent associated with our BART technology in the EU is an important value-building milestone for Lumora.   Having a unique & secure IP position in the area of molecular diagnostics offers substantial and exciting opportunities for the company’s commercial development.”
Presently, Lumora's focus is to bring affordable molecular-based diagnostic products to the food sector. Such products will be applied to pathogen detection but also other emerging needs in the food sector such as GM crop detection. And in 2006 Lumora became the first company to receive investment from the newly established Tate & Lyle Ventures.
Lumora was established in 2002 by Dr. Laurence Tisi and Professor Jim Murray of the University of Cambridge’s Institute of Biotechnology. The company received seed investment in 2004 from the Cambridge Enterprise Seed Funds and a consortium of private investors lead by Peter Kohl and were joined by entrepreneur, Chris Keigthley, who continues to play a pivotal role as Chairman. 
For further details about Lumora please contact:
Dr Laurence Tisi, Acting CEO & Co-Founder, Lumora Ltd
About Lumora Ltd
Lumora was established in 2002 by two leading academics in the field of biotechnology, Dr. Laurence Tisi and Professor Jim Murray from Cambridge University’s Institute of Biotechnology. Lumora started operations in 2003 developing novel assays for the military, received Seed investment in March 2004 from a set of private investors headed by Business Angel Peter Kohl and the University of Cambridge Challenge Fund and obtained over £500,000 in grants and awards between 2004 and present. Dr. Chris Keightley became Lumora’s Chairman following the Seed-Round and continues to play a key strategic role in the company. Significantly, in June 2006 Lumora announced a key licensing deal with the French company bioMérieux, giving Lumora an IP position to produce products for the food sector. 
About Cambridge Enterprise Seed Funds
Cambridge Enterprise Seed Funds provides funding for early stage businesses that have been founded by researchers at the University of Cambridge. Cambridge Enterprise Seed Funds comprises the University Challenge Fund and Venture Fund. The University Challenge Fund was established in 2000 with start up funds from the University of Cambridge, the Wellcome Trust, the Gatsby Foundation and the Office of Science & Technology.   Cambridge Enterprise Seed Funds works alongside Cambridge Enterprise Limited.
Cambridge Enterprise Limited facilitates the commercial development of intellectual property (IP) developed at the University of Cambridge. Cambridge Enterprise is one of the United Kingdom’s leading knowledge transfer offices, licensing patents and other IP to existing companies, both large and small as well as to spinouts formed to exploit University technology. For the academic year ending 2006, 61 licences were entered into and income from licensing exceeded £3.3 million. Additionally consultancy agreements generated £2.9 million.
Working together with angels, venture capital funds, University staff and students, Cambridge Enterprise facilitates the formation of around thirty new companies each year (about five of which are based on University-owned intellectual property).
Further information on Cambridge Enterprise can be found at:    
About Tate & Lyle Ventures

Cambridge Enterprise exists to help University of Cambridge inventors, innovators and entrepreneurs make their ideas and concepts more commercially successful for the benefit of society, the UK economy, the inventors and the University.

Cambridge Enterprise, University of Cambridge